Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 28 May 2009, Vol. 113, No. 22, pp. 5373-5374.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zheng, X. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zheng, X. L.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

THROMBOSIS & HEMOSTASIS

Comment on de Groot et al, page 5609

A team player: the disintegrin domain of ADAMTS13

X. Long Zheng

CHILDREN'S HOSPITAL OF PHILADELPHIA

In this issue of Blood, de Groot and colleagues identify novel interactions between the disintegrin domain of ADAMTS13 and the A2 domain of VWF. This provides another piece in the puzzle of how this domain of ADAMTS13 works in concert with other domains to bind and process VWF.

ADAMTS13, a member of A disintegrin and metalloprotease with thrombospondin type 1 repeats (ADAMTS) family,1,2 is a multidomain glycoprotein found in plasma.3 It consists of numerous domains including a metalloprotease domain, a disintegrin domain, first thrombospondin type 1 (TSP1) repeat, a cysteine-rich domain, and a spacer domain (see panel A in the figure). These are followed by 7 more TSP1 repeats and 2 CUB (complement c1r/c1s, sea urchin epidermal growth factor, and bone morphogenetic protein) domains (figure panel A). ADAMTS13 makes a precise cut on the von Willebrand factor (VWF) molecule after the amino acid residue Tyr1605 at the central A2 domain. This proteolytic cleavage is essential to reduce the size of VWF polymers so that they remain functional enough to stop bleeding, but not so sticky as to cause unwanted thromboses in the small arterioles.4,5 However, it is still unclear how each of the ADAMTS13 domains contributes to the binding and proteolytic processing of VWF under physiologic conditions.

Previous studies have shown that the metalloprotease domain of ADAMTS13 alone is ineffective in cleaving VWF,6,7 but if the various noncatalytic domains are incrementally added back, proteolytic activity is gradually restored.6,7 These results suggest a linear relationship between the domains of ADAMTS13 and VWF proteolysis. Gao et al8 have identified several potential sites on the VWF-A2 domain that may make direct contacts with various proximal noncatalytic domains of ADAMTS13 under static conditions. This result is in agreement with that reported previously by Ai et al,6 in which ADAMTS13 variants truncated after the spacer domain with an additional internal deletion of either disintegrin domain or disintegrin plus TSP1-1 repeat have markedly reduced proteolytic activity toward VWF fragment and exhibit no proteolytic activity toward full-length VWF. Collectively, these data support a hypothesis that all the proximal noncatalytic domains of ADAMTS13 are required for productive engagement with VWF-A2 domain at least under static/denaturing conditions.

In this issue of Blood, de Groot et al9 focus on the involvement of the disintegrin domain of ADAMTS13 in VWF processing in more detail. They use molecular modeling (panel B in the figure) and site-directed mutagenesis to identify the amino acid residues within this domain that are essential for successful cleavage of VWF. They show that 3 out of 8 ADAMTS13 disintegrin mutants they have produced exhibit dramatically reduced activity toward VWF fragment, namely VWF115 (amino acid residues 1554-1668 of VWF), and full-length VWF polymers under static/denaturing conditions.9 Kinetic analyses show a 5- to 20-fold reduction in the catalytic efficiency in cleavage of VWF115 by these mutants.9 Further experiments have identified that the positively charged Arg349 on ADAMTS13 appears to directly interact with the negatively charged Asp1614 on the VWF-A2 domain (figure panel B).9 The authors hypothesize that this seemingly weak interaction between the disintegrin and VWF-A2 appears to be essential for efficient catalysis of VWF under static/denaturing conditions. This task may be achieved in collaboration with other proximal noncatalytic domains. Indeed, the first TSP1 repeat, the Cys-rich domain, and the spacer domains bind VWF-A2 fragment with higher affinity than the disintegrin domain.6 These results suggest that binding of all the proximal noncatalytic domains of ADAMTS13 to VWF is necessary to position the active site of ADAMTS13 to the scissile bond (Tyr1605-Met1606) on VWF, resulting in productive cleavage.

It remains to be seen how this domain functions in concert with the other domains of ADAMTS13 in the presence of shear stress that alters VWF conformation in a more physiologic way. Could it be that the other domains of ADAMTS13 are more important than the disintegrin domain in binding VWF in order to align it with the scissile bond for cleavage in vivo? For instance, the recent report by Zhang et al 10 suggests a role of the middle and distal parts of the noncatalytic region in participating in binding and proteolytic processing of VWF under fluid shear stress. Therefore, further investigation of the precise interactions between each of ADAMTS13 domains and VWF may shed light on understanding the pathogenesis of thrombotic thrombocytopenic purpura, a potentially fatal illness caused primarily by the absence of plasma ADAMTS13 proteolytic activity, as a result of ADAMTS13 mutations or acquired autoantibodies against ADAMTS13 enzyme.


Figure 1
View larger version (56K):
[in this window]
[in a new window]

 
(A) Schematic domain structure of ADAMTS13. Human ADAMTS13 is composed of a catalytic region (ie, metalloprotease domain [MP]) and noncatalytic region that is divided into 3 parts: the proximal, middle, and distal. The proximal noncatalytic part has a disintegrin domain (Dis), first thrombospondin type 1 (TSP1) repeat, a cysteine-rich domain (Cys), and a spacer domain. The middle and distal noncatalytic regions contain 7 more TSP1 repeats and CUB domain, respectively. (B) Homolog model of the metalloprotease and disintegrin domains of ADAMTS13. The metalloprotease domain is shown in light blue. Three active sites His and catalytic residues Glu (dark blue) coordinates a catalytic Zn2+ ion (pink). The disintegrin domain is depicted in light green, light pink, and red. The hypervariable region (HVR) is highlighted in light pink with Arg349 and Leu350 highlighted in red. These 3 amino acids lie adjacent to the active site cleft. Arg349 is located approximately 26 Å from the active site Zn2+. See the complete figure in the article beginning on page 5609.

 

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494.[CrossRef][Medline] [Order article via Infotrieve]

  2. Zheng XL, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063.[Abstract/Free Full Text]

  3. Soejima K, Nakamura H, Hirashima M, et al. Analysis on the molecular species and concentration of circulating ADAMTS13 in blood. J Biochem (Tokyo). 2006;139:147–154.[Abstract/Free Full Text]

  4. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Path Mech Dis. 2008;3:249–277.[CrossRef]

  5. Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007;5:583–589.[CrossRef][Medline] [Order article via Infotrieve]

  6. Ai J, Smith P, Wang S, et al. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005;280:29428–29434.[Abstract/Free Full Text]

  7. Gao W, Anderson PJ, Majerus EM, et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A. 2006;103:19099–19104.[Abstract/Free Full Text]

  8. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood. 2008;112:1713–1719.[Abstract/Free Full Text]

  9. de Groot R, Bardhan A, Ramroop N, Lane DA, Crawley JTB. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood. 2009;113:5609–5616.[Abstract/Free Full Text]

  10. Zhang P, Pan W, Rux AH, et al. The cooperative activity between the carboxyl-terminal TSP-1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood. 2007;110:1887–1894.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Essential role of the disintegrin-like domain in ADAMTS13 function
Rens de Groot, Ajoy Bardhan, Nalisha Ramroop, David A. Lane, and James T. B. Crawley
Blood 2009 113: 5609-5616. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zheng, X. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zheng, X. L.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020